Fusen Pharmaceutical Company Limited (HKG:1652)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.010
-0.060 (-5.61%)
Jul 31, 2026, 3:43 PM HKT
Market Cap746.69M +180.6%
Revenue (ttm)304.20M -16.2%
Net Income-13.11M
EPS-0.02
Shares Out 739.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume36,000
Open1.040
Previous Close1.070
Day's Range1.010 - 1.040
52-Week Range0.300 - 1.750
Beta0.27
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About HKG:1652

Fusen Pharmaceutical Company Limited, an investment holding company, engages in the manufacturing and sale of pharmaceutical products in the People’s Republic of China. The company offers Shuanghuanglian oral solutions and injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; Flunarizine hydrochloride capsules; Sanhuang tablets; compound ferrous sulfate granules; and other pharmaceutical products. It is also involved in manufacturing and sale of pharmaceutical package materials; research and development of pharmaceutical p... [Read more]

Sector Healthcare
Founded 2003
Employees 1,005
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1652
Full Company Profile

Financial Performance

In 2025, HKG:1652's revenue was 273.37 million, a decrease of -16.15% compared to the previous year's 326.03 million. Losses were -11.78 million, -93.76% less than in 2024.

Financial numbers in CNY Financial Statements